24 May 2013
Keywords: Sanofi, Zacks Equity Research, Neutral rating
Article | 05 January 2012
Analysts at USA-based Zacks Equity Research say they are reaffirming their Neutral stance on Sanofi (Euronext: SAN) with a target ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
5 January 2012
4 January 2012
6 January 2012
© 2013 thepharmaletter.com